Abstract
Peripheral arterial occlusive disease (PAD) describes vascular disorders associated with ischemia and PAD affects about 8 million people in the United States. Moreover, PADs prevalence can increase dramatically if cardiovascular disease is present. In healthy individuals reducing blood flow through the lower extremity is followed by a physiological process to limit ischemia in the distal tissue. This process is called revascularization and impairing revascularization results in PAD. Studies suggest nitric oxide (NO) maybe involved in the ischemia-dependent hindlimb revascularization process. NO is increased in the ischemic hindlimb and eliminating NO impairs the revascularization process. Moreover, restoring NO improves hindlimb revascularization. NO may be acting through its effects on vascular tone, cell migration, or extracellular matrix degradation. The present review illustrates nitric oxides critical role in the ischemia-induced hindlimb revascularization. Thus, restoring normal NO levels in diseased arteries may represent a viable therapeutic avenue by supplementing exogenous NO or employing therapeutic strategies to either increase NO synthesis and its messengers or decrease NO catabolism.
Keywords: Angiogenesis, arteriogenesis, nitric oxide, revasculatization, peripheral arterial disease
Current Pharmaceutical Design
Title: Nitric Oxide-Dependent Neovascularization Role in the Lower Extremity Disease
Volume: 13 Issue: 35
Author(s): Monica G. Arellano Mendoza, Hilda Vargas Robles, Eunice Romo, Amelia Rios and Bruno Escalante
Affiliation:
Keywords: Angiogenesis, arteriogenesis, nitric oxide, revasculatization, peripheral arterial disease
Abstract: Peripheral arterial occlusive disease (PAD) describes vascular disorders associated with ischemia and PAD affects about 8 million people in the United States. Moreover, PADs prevalence can increase dramatically if cardiovascular disease is present. In healthy individuals reducing blood flow through the lower extremity is followed by a physiological process to limit ischemia in the distal tissue. This process is called revascularization and impairing revascularization results in PAD. Studies suggest nitric oxide (NO) maybe involved in the ischemia-dependent hindlimb revascularization process. NO is increased in the ischemic hindlimb and eliminating NO impairs the revascularization process. Moreover, restoring NO improves hindlimb revascularization. NO may be acting through its effects on vascular tone, cell migration, or extracellular matrix degradation. The present review illustrates nitric oxides critical role in the ischemia-induced hindlimb revascularization. Thus, restoring normal NO levels in diseased arteries may represent a viable therapeutic avenue by supplementing exogenous NO or employing therapeutic strategies to either increase NO synthesis and its messengers or decrease NO catabolism.
Export Options
About this article
Cite this article as:
Arellano Mendoza G. Monica, Robles Vargas Hilda, Romo Eunice, Rios Amelia and Escalante Bruno, Nitric Oxide-Dependent Neovascularization Role in the Lower Extremity Disease, Current Pharmaceutical Design 2007; 13 (35) . https://dx.doi.org/10.2174/138161207782794103
DOI https://dx.doi.org/10.2174/138161207782794103 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hematopoietic Stem Cells: Transcriptional Regulation, Ex Vivo Expansion and Clinical Application
Current Molecular Medicine Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Role of Polymorphisms in Factor V (FV Leiden), Prothrombin, Plasminogen Activator Inhibitor Type-1 (PAI-1), Methylenetetrahydrofolate Reductase (MTHFR) and Cystathionine β-Synthase (CBS) Genes as Risk Factors for Thrombophilias
Mini-Reviews in Medicinal Chemistry Synthesis, Biological Evaluation and Molecular Docking Studies of Pyridine Incorporated Chalcone Derivatives as Anticancer Agents
Letters in Organic Chemistry Ceramide Involvement in Apoptosis and Apoptotic Diseases
Mini-Reviews in Medicinal Chemistry Impact of the Renin-Angiotensin-Aldosterone-System on Cardiovascular and Renal Complications in Diabetes Mellitus
Current Vascular Pharmacology Somatostatin: A Hormone for the Heart?
Current Vascular Pharmacology How to Identify Subjects with Poly-Vascular Disease?
Current Vascular Pharmacology Role of microRNAs on Blood Brain Barrier Dysfunction in Vascular Cognitive Impairment
Current Drug Delivery Electroacupuncture Reduces Hemiplegia Following Acute Middle Cerebral Artery Infarction with Alteration of Serum NSE, S-100B and Endothelin
Current Neurovascular Research Pharmacological Activity of Cardiovascular Agents from Herbal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of C Reactive Protein (CRP) in Leptin Resistance
Current Pharmaceutical Design The Pathophysiology of Uric Acid in Relation to Cardiovascular Disease
Current Cardiology Reviews LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases
Current Drug Targets Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology Seeing Genes at Work in the Living Brain with Non-Invasive Molecular Imaging
Current Gene Therapy Glycoxidation of Low Density Lipoprotein in Impaired Glucose Tolerance: Implications for the Pathogenesis of Diabetic Vascular Disease
Vascular Disease Prevention (Discontinued) The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism ISCHEMIRs: Finding a Way Through the Obstructed Cerebral Arteries
Current Drug Targets Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design